➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Dow
AstraZeneca
Express Scripts
Merck

Last Updated: December 4, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,192,719

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,192,719
Title:Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Abstract: A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.
Inventor(s): Larsen; Finn (Edinburgh, GB)
Assignee: Aeterna Zentaris GmbH (Frankfurt, DE)
Application Number:12/279,805
Patent Claims: 1. A method of assessing growth hormone deficiency in a human or animal subject, the method comprising: administering orally to the subject EP 1572 or EP 1573, obtaining at least one post-administration sample from the subject, determining the level of growth hormone in the at least one sample and comparing the level of growth hormone in the at least one sample to a level of growth hormone in an equivalent post-administration sample from a subject known not to have growth hormone deficiency and/or a level of growth hormone in an equivalent post-administration sample from a subject known to have growth hormone deficiency to assess whether the level of growth hormone in the at least one sample is indicative of growth hormone deficiency in the subject.

2. A method according to claim 1 wherein a pre-administration sample is taken before the administration of EP 1572 or EP 1573.

3. A method according to claim 1 wherein one or more post-administration sample or samples are taken after a suitable time interval.

4. A method according to claim 3 wherein the time interval can be between 15 and 30 minutes between each sample.

5. A method according to claim 1 wherein samples are taken at -30 or -15, 0, 15, 30, 60, 90 and 120 minutes relative to the time of oral administration of EP 1572 or EP 1573.

6. A method according to claim 1 wherein the assessment of the peak level of growth hormone released during the time frame is used to indicate growth hormone deficiency in the subject.

7. A method of assessing growth hormone deficiency in a human or animal subject, the method comprising: providing at least one post-administration sample from a subject who has been orally administered EP 1572 or EP 1573, determining the level of growth hormone in the at least one sample and comparing the level of growth hormone in the at least one sample to a level of growth hormone in an equivalent post-administration sample from a subject known not to have growth hormone deficiency and/or a level of growth hormone in an equivalent post-administration sample from a subject known to have growth hormone deficiency to assess whether the level of growth hormone in the at least one sample is indicative of growth hormone deficiency in the subject.

8. A method according to claim 7 wherein a sample from the subject prior to the administration of EP 1572 or EP 1573 is provided.

9. A method according to claim 7 wherein one or more post-administration sample or samples taken after a suitable time interval are provided.

10. A method according to claim 9 wherein the time interval can be between 15 and 30 minutes.

11. A method according to claim 7 wherein samples taken at -30 or -15, 0, 15, 30, 60, 90 and 120 minutes relative to the time of oral administration of EP 1572 or EP 1573 are provided.

12. A method according to claim 7 wherein the assessment of the peak level of growth hormone released during the time frame is used to indicate growth hormone deficiency in the subject.

13. A method according to claim 7 wherein the human or animal subject may be either a child or an adult.

14. A method according to claim 7 wherein the animal subject is a horse, cow, sheep, pig, goat, cat or dog.

15. The method of claim 7 wherein the amount of EP 1572 or EP 1573 administered to the subject is between 18 and 75 mg.

16. A method according to claim 7 wherein the at least one sample is a blood sample, a serum sample or a plasma sample.

17. A method according to claim 7 wherein the level of growth hormone in the at least one sample is measured using an immunoassay.

18. A kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.

19. A kit of parts according to claim 18 further comprising a set of instructions on the use of the diagnostic kit, setting out the steps needed to arrive at a diagnosis.

20. A kit of parts according to claim 18 wherein the means for determining the level of growth hormone in a sample is an immunoassay.

21. A method according to claim 1 wherein the human or animal subject may be either a child or an adult.

22. A method according to claim 1 wherein the animal subject is a horse, cow, sheep, pig, goat, cat or dog.

23. The method of claim 1 wherein the amount of EP 1572 or EP 1573 administered to the subject is between 18 and 75 mg.

24. A method according to claim 1 wherein the at least one sample is a blood sample, a serum sample or a plasma sample.

25. A method according to claim 1 wherein the level of growth hormone in the at least one sample is measured using an immunoassay.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Dow
Mallinckrodt
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.